Pharma channel feed – Endpoints News

Pharma channel feed

Personal turf is ‘out,’ community workplaces are ‘in’ at the new Roche neighborhood

8 years ago

After two years of negotiations, FDA gets its user fee programs authorized through 2022

8 years ago

Ironwood looks to boost gout franchise as FDA delivers OK for Duzallo

8 years ago

Struggling AstraZeneca ups the ante on mRNA pipeline work

8 years ago

Samsung Bioepis switches gears, moves from knockoffs to new drugs with fast-changing Takeda

8 years ago

Watch out Tesaro, AstraZeneca and Merck get FDA OK for broad use of Lynparza

8 years ago

Pfizer's CD22-targeted cancer drug inotuzumab wins an accelerated OK at FDA

8 years ago

Arcus grabs US rights to a WuXi-built PD-1 as second wave of checkpoints builds

8 years ago

Price gouging on drugs? Shkreli's jury selection process reveals some deep public anger

8 years ago

Aerie boosted as Valeant's troubled Tampa facility looks like it's coming out of rehab

8 years ago

J&J's Alex Gorsky reverses course and jumps ship — just as Trump scuttles top CEO groups

8 years ago

New study of FDA cites the flaws behind rapid-fire cancer drug OKs

8 years ago

Celgene-partnered Antengene preps new China deals as $21M round lands

8 years ago

Feds offer up a new bonus plan for the R&D work they often pay for

8 years ago

As Trump lashes out at Frazier again, J&J's Alex Gorsky says he's not abandoning president's council

8 years ago

What's worth $500M-plus? The Big 6 deals of Q2 show you where the money is — and isn't

8 years ago

Is Amazon planning to disrupt the $560B prescription drug market?

8 years ago

J&J beefs up neuro pipeline, bags a new depression drug from Cerecor in $45M deal

8 years ago

Merck CEO Ken Frazier resigns from Trump council in protest, and the president swiftly bites back

8 years ago

Focused on data and drug development, SoftBank hunts new $1B biotech deals — report

8 years ago

Mundipharma picks up a PhIII-ready chemo creation in $250M deal

8 years ago

GSK abandons Ionis' FDA-ready inotersen as new CEO sweeps out rare disease efforts

8 years ago

Dicerna escalates war with Alnylam over RNAi secrets, claiming its rival wants a monopoly

8 years ago

Gilead circles February 12 on its calendar as D-day for its HIV franchise

8 years ago

First page Previous page 316 317 318319320 321 322 Next page Last page